Advertisement.

BVNKF Projected Dividend Yield

Ord/Bavarian Nordic A/S ( OTCBB : BVNKF )

Bavarian Nordic is a fully integrated biotechnology company developing, manufacturing and commercializing vaccines for the prevention and treatment of life-threatening diseases. Co.'s commercial products are: Jynneos/Imvamune/Imvanex, for prevention of smallpox and monkeypox; Rabipur/Rabavert, a vaccine for rabies; and Encepur, a vaccine for tick-borne encephalitis (TBE). Co.'s product candidates are: MVA-BN (freeze dried), a treatment for smallpox; MVA-BN RSV, a treatment of bronchiolitis and pneumonia; MVA-BN Filo, a treatment for Ebola; MVA-BN WEV, a treatment for Equine encephalitis; MVA-BN HPV, a treatment for HPV; and BN-Brachyury, a treatment for Chordoma.

20 YEAR PERFORMANCE RESULTS

BVNKF Dividend History Detail
BVNKF Dividend News
BVNKF Competitors News

# of Shares: 0

Closing Price: 27.78

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000